12,031 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 2nd quarter, HoldingsChannel reports. The firm acquired 12,031 shares of the company’s stock, valued at approximately $1,457,000.

A number of other hedge funds have also made changes to their positions in MIRM. Janus Henderson Group PLC raised its holdings in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter worth approximately $513,945,000. Vanguard Group Inc. increased its position in shares of Mirum Pharmaceuticals by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after purchasing an additional 50,720 shares in the last quarter. State Street Corp increased its position in shares of Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Mirum Pharmaceuticals by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after purchasing an additional 137,087 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $98.05 on Tuesday. Mirum Pharmaceuticals, Inc. has a one year low of $63.23 and a one year high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The stock has a market cap of $6.37 billion, a PE ratio of -6.74 and a beta of 0.52. The stock has a 50 day moving average price of $110.44 and a 200 day moving average price of $101.78.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.12) EPS. Equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the transaction, the senior vice president owned 1,274 shares in the company, valued at $127,400. The trade was a 96.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $98.92, for a total value of $1,978,400.00. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $19,221,046.28. This represents a 9.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 103,156 shares of company stock valued at $10,888,362 in the last three months. 8.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on MIRM. Robert W. Baird set a $123.00 price objective on Mirum Pharmaceuticals in a report on Thursday, August 6th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. UBS Group set a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday. Evercore reissued an “outperform” rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Citizens Jmp restated a “market outperform” rating and set a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $137.31.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.